Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results from the Mid-Adult Male Vaccine Trial

Journal of Infectious Diseases

Volumn 214, Issue 8, 2016, Pages 1276-1283

  Pinto, Ligia A ^a   Kemp, Troy J ^a   Torres, B Nelson ^b   Isaacs Soriano, Kimberly ^b   Ingles, Donna ^b   Abrahamsen, Martha ^b   Pan, Yuanji ^a   Lazcano Ponce, Eduardo ^c   Salmeron, Jorge ^c   Giuliano, Anna R ^b  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

Author keywords

HPV vaccine; Males; Mouthwash; Saliva; Serum

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; WART VIRUS VACCINE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADULT; ALCOHOL CONSUMPTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; GINGIVA BLEEDING; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUTH CAVITY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; TOBACCO USE; TOOTH BRUSHING; VIRUS DETECTION; VIRUS LIKE AGENT; FLORIDA; IMMUNOLOGY; MEXICO; MOUTH; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; SALIVA; VACCINATION;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; FLORIDA; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; IMMUNOGLOBULIN G; MALE; MEXICO; MIDDLE AGED; MOUTH; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SALIVA; VACCINATION;

EID: 84990990258     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw359     Document Type: Article

References (23)

1. Petersen PE. Oral cancer prevention and control-the approach of the World Health Organization. Oral Oncol 2009; 45:454-60.
2. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29:4294-301.
3. Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013; 105:175-201.
4. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011; 364:401-11.
5. Giuliano AR, Isaacs-Soriano K, Torres BN, et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)-The MAM Study. Vaccine 2015; 33:5640-6.
6. Herrero R, Quint W, Hildesheim A, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One 2013; 8:e68329.
7. Kemp TJ, Safaeian M, Miner S, et al. Oral immunoglobulin levels are not a good surrogate for cervical immunoglobulin levels. Front Oncol 2012; 2:61.
8. Pierce Campbell CM, Guan W, Sprung R, et al. Quantification of secretory leukocyte protease inhibitor (SLPI) in oral gargle specimens collected using mouthwash. J Immunol Methods 2013; 400-401:117-21.
9. Kreimer AR, Pierce Campbell CM, Lin HY, et al. Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet 2013; 382:877-87.
10. Dauner JG, Pan Y, Hildesheim A, Harro C, Pinto LA. Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine. Vaccine 2010; 28:5407-13.
11. Dauner JG, Pan Y, Hildesheim A, Kemp TJ, Porras C, Pinto LA. Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals. Mol Cell Probes 2012; 26:73-80.
12. Dessy FJ, Giannini SL, Bougelet CA, et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 2008; 4:425-34.
13. Romanowski B, Schwarz TF, Ferguson L, et al. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modelling predictions from a randomized study. Hum Vaccin Immunother 2016; 12:20-9.
14. Anayannis NV, Schlecht NF, Belbin TJ. Epigenetic mechanisms of human papillomavirus-associated head and neck cancer. Arch Pathol Lab Med 2015; 139:1373-8.
15. Munoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009; 373:1949-57.
16. Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nat Rev Cancer 2006; 6:753-63.
17. Kreimer AR, Gonzalez P, Katki HA, et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol 2011; 12:862-70.
18. Pierce Campbell CM, Kreimer AR, Lin HY, et al. Long-term persistence of oral human papillomavirus type 16: the HPV Infection in Men (HIM) study. Cancer Prev Res (Phila) 2015; 8:190-6.
19. Brokstad KA, Cox RJ, Olofsson J, Jonsson R, Haaheim LR. Parenteral influenza vaccination induces a rapid systemic and local immune response. J Infect Dis 1995; 171:198-203.
20. Brokstad KA, Eriksson JC, Cox RJ, et al. Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa. J Infect Dis 2002; 185:878-84.
21. Brandtzaeg P. Secretory immunity with special reference to the oral cavity. J Oral Microbiol 2013; 5:20401-24.
22. Granade TC, Phillips SK, Kitson-Piggott W, et al. Influence of host factors on immunoglobulin G concentration in oral fluid specimens. Clin Diagn Lab Immunol 2002; 9:194-7.
23. Rowhani-Rahbar A, Carter JJ, Hawes SE, et al. Antibody responses in oral fluid after administration of prophylactic human papillomavirus vaccines. J Infect Dis 2009; 200:1452-5.